Phaseline

Companies › Aesculap Biologics

Aesculap Biologics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 3; Other; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NOVOCART 3D
Matrix associated autologous chondrocyte implant
–Phase 3Articular Cartilage of the Femoral Condyle Between 2-6cm2; Articular Cartilage DefectDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT01957722NOVOCART 3DPhase 3Articular Cartilage of the Femoral Condyle Between 2-6cm2OtherDec 2027
NCT03219307NOVOCART 3DPhase 3Articular Cartilage DefectOtherJan 2029

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Metcela OHB Pediatrics CoNextions Medical ULURU DiscGenics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.